Market Cap 2.99B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 14,848,000
Avg Vol 7,708,258
Day's Range N/A - N/A
Shares Out 306.61M
Stochastic %K 99%
Beta 1.20
Analysts Strong Sell
Price Target $13.00

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
tiddyy
tiddyy Aug. 13 at 1:05 PM
$ABCL Next stop is the IPO price at $20
0 · Reply
Jthomp11
Jthomp11 Aug. 13 at 1:01 PM
$ABCL I'm Having Hot Flashes 🚀
0 · Reply
JennyRowes
JennyRowes Aug. 13 at 12:47 PM
$ABCL well $9.75 is the new floor, with lots of pent up institutionsl demand ready to buy. This game has just fundamentally changed. 15 months ago this was a $2 stock! Up 5x in 5 quarters!
0 · Reply
desmondekici
desmondekici Aug. 13 at 12:46 PM
$ONDS $ABCL $AIRO my system says too late!
0 · Reply
DeMampCamp
DeMampCamp Aug. 13 at 12:33 PM
$ABCL Crazy volume this morning, I still remember years ago when we struggled to even trade a million shares the entire day, we've come a long ways! Cheers everyone and happy Thursday!
2 · Reply
Jimbates22
Jimbates22 Aug. 13 at 12:16 PM
$ABCL it’s cute that people are talking about volatility over the next several years. We all know bears either shorted the stock on the big spike in the $9’s or loaded up on $10 and $9 strike puts expiring in the next three months.
0 · Reply
Jimbates22
Jimbates22 Aug. 13 at 12:03 PM
$ABCL going to repost this. My prediction came true. Keep in mind that $9.75 was ABOVE the SP at the time this was negotiated. The one catalyst for shorts is in the rear view mirror and it’s a big disappointment for them.
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Aug. 13 at 11:42 AM
$ABCL 12 end of week , poor bears are toast
0 · Reply
FreyBentos
FreyBentos Aug. 13 at 11:22 AM
$ABCL That gap below is worrying, we may head to fill it but if so I think it could be a dip buying opportunity. Still years away from revs here, next year or two are gona be volatile here with big swings (If you've followed other biotech going through phase 2/3 approval you'll know the deal). Hoping we come through with full approval in a year or two thus making the path back to $20 and above viable
0 · Reply
JeanPCocotte
JeanPCocotte Aug. 13 at 11:03 AM
$ABCL And AGAIN, it was only BS on the offering price by the bears... 9,75$ is almost exactly the same price the stock was the day they made the announcement! They are done...
0 · Reply
Latest News on ABCL
AbCellera announces $200M common stock, warrants offering

2026-08-11T20:05:47.000Z - 1 day ago

AbCellera announces $200M common stock, warrants offering


AbCellera price target raised to $30 from $12 at Truist

2026-08-11T13:35:37.000Z - 1 day ago

AbCellera price target raised to $30 from $12 at Truist


AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 8:00 AM EDT - 3 days ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 3 days ago

AbCellera Biologics Transcript: Study result


AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 3 days ago

AbCellera Biologics Press release: Study result


AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:30 AM EDT - 3 days ago

AbCellera Biologics Slides: Study result


AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:20:50.000Z - 7 days ago

AbCellera price target raised to $9 from $8 at Stifel


AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 7 days ago

AbCellera Biologics Earnings Call Transcript: Q2 2026


AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 7 days ago

AbCellera Biologics Slides: Q2 2026


AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 7 days ago

AbCellera Biologics Earnings release: Q2 2026


AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 7 days ago

AbCellera Biologics Quarterly report: Q2 2026


AbCellera Reports Q2 2026 Business Results

Aug 5, 2026, 4:05 PM EDT - 7 days ago

AbCellera Reports Q2 2026 Business Results


AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 5 weeks ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ


AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 5 weeks ago

AbCellera apponts Lynn Seely to board of directors

LYEL


AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 5 weeks ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors


AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 2 months ago

AbCellera appoints Victor Sandor to board of directors


AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 3 months ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Slides: Q1 2026


AbCellera Biologics Slides: Corporate presentation

May 1, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 9 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


tiddyy
tiddyy Aug. 13 at 1:05 PM
$ABCL Next stop is the IPO price at $20
0 · Reply
Jthomp11
Jthomp11 Aug. 13 at 1:01 PM
$ABCL I'm Having Hot Flashes 🚀
0 · Reply
JennyRowes
JennyRowes Aug. 13 at 12:47 PM
$ABCL well $9.75 is the new floor, with lots of pent up institutionsl demand ready to buy. This game has just fundamentally changed. 15 months ago this was a $2 stock! Up 5x in 5 quarters!
0 · Reply
desmondekici
desmondekici Aug. 13 at 12:46 PM
$ONDS $ABCL $AIRO my system says too late!
0 · Reply
DeMampCamp
DeMampCamp Aug. 13 at 12:33 PM
$ABCL Crazy volume this morning, I still remember years ago when we struggled to even trade a million shares the entire day, we've come a long ways! Cheers everyone and happy Thursday!
2 · Reply
Jimbates22
Jimbates22 Aug. 13 at 12:16 PM
$ABCL it’s cute that people are talking about volatility over the next several years. We all know bears either shorted the stock on the big spike in the $9’s or loaded up on $10 and $9 strike puts expiring in the next three months.
0 · Reply
Jimbates22
Jimbates22 Aug. 13 at 12:03 PM
$ABCL going to repost this. My prediction came true. Keep in mind that $9.75 was ABOVE the SP at the time this was negotiated. The one catalyst for shorts is in the rear view mirror and it’s a big disappointment for them.
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Aug. 13 at 11:42 AM
$ABCL 12 end of week , poor bears are toast
0 · Reply
FreyBentos
FreyBentos Aug. 13 at 11:22 AM
$ABCL That gap below is worrying, we may head to fill it but if so I think it could be a dip buying opportunity. Still years away from revs here, next year or two are gona be volatile here with big swings (If you've followed other biotech going through phase 2/3 approval you'll know the deal). Hoping we come through with full approval in a year or two thus making the path back to $20 and above viable
0 · Reply
JeanPCocotte
JeanPCocotte Aug. 13 at 11:03 AM
$ABCL And AGAIN, it was only BS on the offering price by the bears... 9,75$ is almost exactly the same price the stock was the day they made the announcement! They are done...
0 · Reply
Planetpaprika
Planetpaprika Aug. 13 at 10:47 AM
$ABCL ...only a modest discount to the ~$10.38 area. Good. The offering was oversubscribed, that's a strong signal of institutional demand. Good. Because investors were willing to put $200M into ABCL at essentially the current post-data valuation. That validates the new valuation level much more than a heavily discounted financing would. Good. The downside is straightforward: we shareholders are diluted. If there were roughly 170M shares outstanding beforehand, ~20.5M incremental shares would represent roughly 12% dilution. If I´m right, 17.44M shares + 3.08M pre-funded warrants....But the company receives $200M cash in return, so the dilution isn't equivalent to simply destroying 12% of shareholder value. And long-term its positive for ABCL635. Good. :-) IMO... https://www.theglobeandmail.com/investing/markets/stocks/ABCL-Q/pressreleases/3818923/abcellera-announces-pricing-of-oversubscribed-200-million-public-offering-of-common-shares-and-pre-funded-warrants/
0 · Reply
toni1965
toni1965 Aug. 13 at 10:05 AM
$ABCL Impressive secondary offering pricing
0 · Reply
SwingTrades1
SwingTrades1 Aug. 13 at 8:39 AM
$ABCL Oversubscribed at $9.75, with 85% in common shares and the remaining 15% in pre-funded warrants. The tape is telling the story. Shorts look increasingly boxed in for the near term. Now let’s see who the new players are once the filings start rolling in. https://www.streetinsider.com/dr/news.php?id=26914990
0 · Reply
psyxopathis
psyxopathis Aug. 13 at 7:54 AM
$ABCL 9.75 per share. WOW! Well played Abcl 👏👏👏
0 · Reply
lustiger
lustiger Aug. 13 at 7:43 AM
$ABCL in range.
0 · Reply
BigPlaySnipers
BigPlaySnipers Aug. 13 at 6:35 AM
$ABCL what a beast broke that $10 First mentioned on the website at $5.69 Link in bio
0 · Reply
Themk
Themk Aug. 13 at 6:00 AM
$ABCL the things that concern me is the partnership shrinking significantly over the years and the lack of success with partners. Especially since they have had success with their own and are going to phase 3 already.
1 · Reply
Plan2TradeTrade2Plan
Plan2TradeTrade2Plan Aug. 13 at 5:56 AM
$ABCL great news: modest dilution, tight pricing, oversubscribed, and the proceeds are earmarked for advancing ABCL635. Moving ahead! 🚀🚀
0 · Reply
tiddyy
tiddyy Aug. 13 at 5:06 AM
$ABCL Wonder if one of the Baker Bros will push for a board seat soon
1 · Reply
STACKD0E
STACKD0E Aug. 13 at 4:42 AM
$ABCL +163% WE DID IT!! 🙃 ✨️
0 · Reply
PolarBear1
PolarBear1 Aug. 13 at 4:39 AM
$ABCL Fantastic pricing given the stock was at $6 ps just a couple of weeks ago. Very very strong here. My guess is that Baker Brothers maintained they’re pro rata position and will still hold just under 10% post issue (if they bought the prefunded warrants)….
0 · Reply
tranq19
tranq19 Aug. 13 at 4:23 AM
$ABCL oversubscribed priced at 9.75! https://lnkd.in/p/gUcjvF6D
0 · Reply